Apart from further exploring the possible benefit of chemical renin-angiotensin-aldosterone system inhibitors in COVID-19 patients, another promising approach might consist of the treatment of COVID-19 with human recombinant soluble ACE2. This evidence concerns the gene REN and COVID-19.